CL2017001471A1 - Nueva estructura de proteína producida por un anticuerpo efectivo usado para inmunización - Google Patents

Nueva estructura de proteína producida por un anticuerpo efectivo usado para inmunización

Info

Publication number
CL2017001471A1
CL2017001471A1 CL2017001471A CL2017001471A CL2017001471A1 CL 2017001471 A1 CL2017001471 A1 CL 2017001471A1 CL 2017001471 A CL2017001471 A CL 2017001471A CL 2017001471 A CL2017001471 A CL 2017001471A CL 2017001471 A1 CL2017001471 A1 CL 2017001471A1
Authority
CL
Chile
Prior art keywords
immunization
protein structure
antibody used
structure produced
new protein
Prior art date
Application number
CL2017001471A
Other languages
English (en)
Inventor
Ming Chung Kan
Original Assignee
Vaxsia Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxsia Biomedical Inc filed Critical Vaxsia Biomedical Inc
Publication of CL2017001471A1 publication Critical patent/CL2017001471A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

<p>UN MÉTODO PARA AUMENTAR UNA RESPUESTA INMUNE, DONDE EL MÉTODO COMPRENDE UNIR COVALENTEMENTE UN PÉPTIDO ANFIFÍLICO A UN ANTÍGENO PARA FORMAR UN COMPUESTO DE COMPLEJO DE ANTÍGENO, Y ADMINISTRAR EL COMPUESTO DE COMPLEJO DE ANTÍGENO A UN INDIVIDUO. EL COMPUESTO DE ANTÍGENO QUE TIENE UNA ESTRUCTURA DE HÉLICE ANFIFÍLICA PUEDE AUMENTAR LA ENTREGA DE ANTÍGENO</p>
CL2017001471A 2014-12-10 2017-06-08 Nueva estructura de proteína producida por un anticuerpo efectivo usado para inmunización CL2017001471A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462090180P 2014-12-10 2014-12-10

Publications (1)

Publication Number Publication Date
CL2017001471A1 true CL2017001471A1 (es) 2018-03-02

Family

ID=56106724

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001471A CL2017001471A1 (es) 2014-12-10 2017-06-08 Nueva estructura de proteína producida por un anticuerpo efectivo usado para inmunización

Country Status (9)

Country Link
US (1) US20180161425A1 (es)
EP (1) EP3231441A4 (es)
JP (1) JP2018500389A (es)
CN (1) CN107106668A (es)
AU (1) AU2015360107A1 (es)
CA (1) CA2970211A1 (es)
CL (1) CL2017001471A1 (es)
TW (2) TWI623322B (es)
WO (1) WO2016091181A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI657824B (zh) * 2017-12-29 2019-05-01 財團法人生物技術開發中心 抗流感之通用疫苗
US20220169680A1 (en) * 2018-11-02 2022-06-02 Institute Of Basic Medical Sciences Chinese Academy Of Medical Sciences Cell-penetrating peptide based on influenza virus m2 protein
JP2023510289A (ja) * 2020-01-09 2023-03-13 ザ ユニバーシティー オブ クイーンズランド ワクチン送達のための自己組織化自己アジュバント系

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0306912A3 (en) * 1987-09-08 1989-07-05 Albany Medical College Immunogenic composites capable of selectively inducing antibody production and pharmaceutical compositions employing the same.
WO2002064057A2 (en) * 2001-02-15 2002-08-22 Baylor College Of Medicine Use of cell penetrating peptides to generate antitumor immunity
WO2004096849A2 (en) * 2003-04-25 2004-11-11 University Of Manitoba Peptide-based cytokine/chemokine vaccines against allergy
GB0613977D0 (en) * 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
CA2730737A1 (en) * 2008-07-15 2010-01-21 Novartis Ag Immunogenic amphipathic peptide compositions
JP4797149B2 (ja) * 2009-10-23 2011-10-19 研爾 奥田 インフルエンザウイルスに対するベクターワクチン
RU2670488C2 (ru) * 2012-09-13 2018-10-23 Юниверсите Де Женев Новые проникающие в клетку пептиды
EP2916873B1 (en) * 2012-11-07 2017-07-26 Council of Scientific & Industrial Research Nanocomplex containing amphipathic peptide useful for efficient transfection of biomolecules
US10111948B2 (en) * 2014-04-25 2018-10-30 Tria Bioscience Corp. Synthetic hapten carrier compositions and methods

Also Published As

Publication number Publication date
TWI683668B (zh) 2020-02-01
TW201627005A (zh) 2016-08-01
EP3231441A1 (en) 2017-10-18
AU2015360107A1 (en) 2017-06-29
CA2970211A1 (en) 2016-06-16
CN107106668A (zh) 2017-08-29
TWI623322B (zh) 2018-05-11
WO2016091181A1 (zh) 2016-06-16
TW201815414A (zh) 2018-05-01
EP3231441A4 (en) 2018-10-31
JP2018500389A (ja) 2018-01-11
US20180161425A1 (en) 2018-06-14

Similar Documents

Publication Publication Date Title
CY1125241T1 (el) Υποδορια σκευασματα αντισωματων anti-cd38 και οι χρησεις τους
DOP2018000259A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
CL2019001198A1 (es) Anticuerpo bioespecífico contra bcma y cd3 y un fármaco inmunológico para uso combinado en el tratamiento de mieloma múltiple.
CY1124521T1 (el) Σκευασματα αντισωματος anti-cd19
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
MX2016012124A (es) Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos.
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
PE20171103A1 (es) Anticuerpos heterodimericos que se unen a cd3 y cd38
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA201891339A1 (ru) Водный фармацевтический препарат, который содержит антитело к pd-l1 авелумаб
CL2018001000A1 (es) Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr.
AR110321A1 (es) Anticuerpos antitau y métodos de uso
MX2021011167A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
AR096687A1 (es) Anticuerpos anti-fcrh5
PE20150002A1 (es) Anticuerpos anti-fcrn
EP4070818A3 (en) Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
AR101846A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
MX2018015272A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
EA201790239A1 (ru) Молекула-носитель для антигенов
MX2018015268A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
MX2018015274A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
NZ729747A (en) Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
CO2017010631A2 (es) Método para purificación de proteína